Clinica e Investigacion en Arteriosclerosis最新文献

{"title":"Riesgo poligénico y aterosclerosis subclínica en individuos asintomáticos de mediana edad. Estudio ILERVAS","authors":"Emilio Ortega ,&nbsp;Amanda Jiménez ,&nbsp;Sheila López-Ruiz ,&nbsp;Eva Castro-Boqué ,&nbsp;José Manuel Valdivielso ,&nbsp;Marcelino Bermúdez-López ,&nbsp;Gemma Chiva-Blanch","doi":"10.1016/j.arteri.2024.11.004","DOIUrl":"10.1016/j.arteri.2024.11.004","url":null,"abstract":"<div><h3>Introduction and objectives</h3><div>More than 50% of first cardiovascular events (CVE) occur in populations identified as at low or intermediate risk by the risk equations, so the inclusion of additional variables, such as polygenic risk scores (PRS), has been proposed to improve the predictive capacity of these equations. The aim of this study was to assess whether a PRS, independently or with clinical risk equations, is associated with the presence, severity and extent of subclinical atherosclerosis.</div></div><div><h3>Methods</h3><div>109 subjects with atherosclerosis were selected from the ILERVAS cohort (primary prevention) and matched with 109 participants without atherosclerosis of the same age, sex and SCORE2 risk level. Atherosclerosis was assessed and quantified by arterial wall vascular ultrasound in 12 territories, and PRS was estimated using the Cardio inCode Score®. The predictive capacity of the presence of subclinical atherosclerosis was estimated, as well as the association between the extent and severity of atherosclerosis with PRS and clinical risk (SCORE2).</div></div><div><h3>Results</h3><div>PRS was similar between participants with or without atherosclerosis <em>(P</em> <!-->=<!--> <!-->0.525). We did not find an association between PRS and SCORE2 (r<!--> <!-->=<!--> <!-->-0.29, <em>P</em> <!-->=<!--> <!-->0.709), and the addition of PRS to SCORE2 did not improve the prediction of atherosclerosis [AUC (95% CI)<!--> <!-->=<!--> <!-->0.566 (0.477, 0.654), <em>P</em> <!-->=<!--> <!-->0.148]. The extent of atherosclerosis was related to SCORE2 (<em>P</em> <!-->=<!--> <!-->0.009), but not to PRS (<em>P</em> <!-->=<!--> <!-->0.709).</div></div><div><h3>Conclusions</h3><div>The Selected PRS is not associated with the presence of atherosclerosis or clinical risk, suggesting that its additional contribution to CVE risk would be mediated by mechanisms independent of the development of atherosclerosis. Additional biomarkers are needed to improve the prediction of subclinical atherosclerosis without using imaging tests as a first step in personalized assessment.</div></div>","PeriodicalId":45230,"journal":{"name":"Clinica e Investigacion en Arteriosclerosis","volume":"37 2","pages":"Article 100751"},"PeriodicalIF":1.9,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142792568","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Los niveles plasmáticos elevados de TNF-R1 predicen el desarrollo de eventos isquémicos agudos en pacientes coronarios con diabetes","authors":"Sebastián Mas-Fontao ,&nbsp;Nieves Tarín ,&nbsp;Carmen Cristóbal ,&nbsp;Manuel Soto-Catalán ,&nbsp;Ana Pello ,&nbsp;Alvaro Aceña ,&nbsp;Jairo Lumpuy-Castillo ,&nbsp;Carmen Garces ,&nbsp;Carmen Gomez-Guerrero ,&nbsp;Carlos Gutiérrez-Landaluce ,&nbsp;Luis M. Blanco-Colio ,&nbsp;José Luis Martín-Ventura ,&nbsp;Ana Huelmos ,&nbsp;Joaquín Alonso ,&nbsp;Lorenzo López Bescós ,&nbsp;Juan A. Moreno ,&nbsp;Ignacio Mahíllo-Fernández ,&nbsp;Óscar Lorenzo ,&nbsp;María Luisa González-Casaus ,&nbsp;Jesús Egido ,&nbsp;José Tuñón","doi":"10.1016/j.arteri.2024.08.004","DOIUrl":"10.1016/j.arteri.2024.08.004","url":null,"abstract":"<div><h3>Objectives</h3><div>To examine the relationship between inflammatory biomarkers and the occurrence of cardiovascular events in patients with type 2 diabetes mellitus (DM2) and stable coronary artery disease.</div></div><div><h3>Methods</h3><div>A total of 964 patients with stable coronary artery disease were included. Plasma levels of inflammatory markers, including tumour necrosis factor receptors 1 and 2 (TNF-R1 and TNF-R2), growth differentiation factor-15 (GDF-15), soluble suppression of tumorigenicity 2 (sST2), and high-sensitivity C-reactive protein (hsCRP) were measured. The primary endpoint was the development of acute ischaemic events (any type of acute coronary syndrome, stroke, or transient ischaemic attack).</div></div><div><h3>Results</h3><div>There were 232 diabetic patients and 732 non-diabetic patients. Patients with coronary artery disease and DM2 (232, 24%) had higher levels of TNF-R1, TNF-R2, GDF-15, sST2 (<em>P</em>&lt;.001), and hsCRP compared to patients without DM2, indicating a higher inflammatory state. After a median follow-up of 5.39 (2.81-6.92) years, patients with DM2 more frequently developed the primary endpoint (15.9% vs 10.8%; <em>P</em>=.035). Plasma levels of TNF-R1 were independent predictors of the primary endpoint in patients with DM2, along with male gender, triglyceride levels, and the absence of treatment with angiotensin-converting enzyme inhibitors. None of these inflammatory markers predicted the development of this event in non-diabetic patients.</div></div><div><h3>Conclusions</h3><div>Patients with stable coronary artery disease and DM2 exhibit elevated levels of the proinflammatory markers TNF-R1, TNF-R2, GDF-15, and sST2. Moreover, TNF-R1 is an independent predictor of acute ischaemic events only in diabetic patients.</div></div>","PeriodicalId":45230,"journal":{"name":"Clinica e Investigacion en Arteriosclerosis","volume":"37 2","pages":"Article 100735"},"PeriodicalIF":1.9,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142355993","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Hábitos nutricionales en los pacientes con enfermedad arterial periférica: adherencia a la dieta mediterránea","authors":"Elena Vilalta Doñate ,&nbsp;Francisca García Fernández ,&nbsp;Salvador Martínez Meléndez ,&nbsp;Consuelo Castillo Castillo ,&nbsp;Pablo Salas Medina ,&nbsp;Isabel Almodóvar Fernández","doi":"10.1016/j.arteri.2024.06.002","DOIUrl":"10.1016/j.arteri.2024.06.002","url":null,"abstract":"<div><h3>Introduction</h3><div>Adherence to the Mediterranean diet (Dietmed) exerts protective effects on cardiovascular disease (CVD). In the Lower Extremity Peripheral Arterial Disease (PAD) there are fewer studies that analyze these data.</div></div><div><h3>Objective</h3><div>To determine adherence to Dietmed and dietary habits in patients with PAD, according to a history of CVD (coronary and/or cerebral ischaemic pathology) and according to the ankle-brachial index (ABI ≥ or &lt;0,5).</div></div><div><h3>Material and methods</h3><div>Cross-sectional analytical study carried out in a tertiary hospital. The sample was collected consecutively. Sociodemographic and clinical history, ankle-brachial index (ABI) and a 14-point Dietmed adherence dietary questionnaire were included. The analysis of categorical variables was carried out using the Pearson's Chi-Square test, the T-Student's statistic test for independent samples was used for parametric variables and the U. Mann-Whitney test for non-parametric variables.</div></div><div><h3>Results</h3><div>Of the 97 patients, 87,6% had low adherence to Dietmed, with no differences according to the severity of PAD. However, when we analysed the data according to whether or not they had a history of CVD, we observed a high adherence to some items included in Dietmed, specifically, in the CVD group, the consumption of lean meat (95,5% vs 64%; <em>P</em>=.004). In addition, we observed a significant difference in the consumption in the group without a history of CVD (32% vs 9,1%; <em>P</em>=.033).</div></div><div><h3>Conclusion</h3><div>In our population, patients with PAD, regardless of the stage of the disease and whether they had associated coronary or cerebral ischaemic pathology, had low adherence to Dietmed. Therefore, it is important to implement nutritional education programmes in patients with PAD in all stages, as well as in those patients who have already suffered a vascular event, so that they maintain adherence to healthy dietary habits in the long term.</div></div>","PeriodicalId":45230,"journal":{"name":"Clinica e Investigacion en Arteriosclerosis","volume":"37 2","pages":"Article 100726"},"PeriodicalIF":1.9,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141628054","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Evaluación del efecto sobre la trombogenicidad de modificaciones de la superficie en stents de nitinol en un modelo in vitro","authors":"Javier Rodríguez Lega,&nbsp;Ángel González Pinto","doi":"10.1016/j.arteri.2024.10.002","DOIUrl":"10.1016/j.arteri.2024.10.002","url":null,"abstract":"","PeriodicalId":45230,"journal":{"name":"Clinica e Investigacion en Arteriosclerosis","volume":"37 1","pages":"Article 100742"},"PeriodicalIF":1.9,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142640066","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Levels of sCD163 in women rheumatoid arthritis: Relationship with cardiovascular risk markers","authors":"Oscar Zaragoza-García ,&nbsp;Olivia Briceño ,&nbsp;José Rafael Villafan-Bernal ,&nbsp;Ilse Adriana Gutiérrez-Pérez ,&nbsp;Héctor Ugo Rojas-Delgado ,&nbsp;Gustavo Adolfo Alonso-Silverio ,&nbsp;Antonio Alarcón-Paredes ,&nbsp;José Eduardo Navarro-Zarza ,&nbsp;Cristina Morales-Martínez ,&nbsp;Rubén Rodríguez-García ,&nbsp;Iris Paola Guzmán-Guzmán","doi":"10.1016/j.arteri.2024.04.002","DOIUrl":"10.1016/j.arteri.2024.04.002","url":null,"abstract":"<div><h3>Aim</h3><div>The soluble scavenger receptor differentiation antigen 163 (sCD163), a monocyte/macrophage activation marker, is related to cardiovascular mortality in the general population. This study aimed to evaluate their relationship between serum levels of sCD163 with cardiovascular risk indicators in rheumatoid arthritis (RA).</div></div><div><h3>Methods</h3><div>A cross-sectional study was performed on 80 women diagnosed with RA. The cardiovascular risks were determined using the lipid profile, metabolic syndrome, and QRISK3 calculator. For the assessment of RA activity, we evaluated the DAS28 with erythrocyte sedimentation rate (DAS28-ESR). The serum levels of sCD163<span> were determined by the ELISA<span> method. Logistic regression models and receiver operating characteristics (ROC) curve were used to assess the association and predictive value of sCD163 with cardiovascular risk in RA patients.</span></span></div></div><div><h3>Results</h3><div>Levels of sCD163 were significantly higher in RA patients with high sensitivity protein C-reactive to HDL-c ratio (CHR)<!--> <!-->≥<!--> <!-->0.121 (<em>p</em> <!-->=<!--> <!-->0.003), total cholesterol/HDL-c ratio<!--> <!-->&gt;<!--> <!-->7% (<em>p</em> <!-->=<!--> <!-->0.004), LDL-c/HDL-c ratio<!--> <!-->&gt;<!--> <!-->3% (<em>p</em> <!-->=<!--> <!-->0.035), atherogenic index of plasma<!--> <!-->&gt;<!--> <!-->0.21 (<em>p</em> <!-->=<!--> <!-->0.004), cardiometabolic index (CMI)<!--> <!-->≥<!--> <!-->1.70 (<em>p</em> <!-->=<!--> <!-->0.005), and high DAS28-ESR (<em>p</em> <!-->=<!--> <!-->0.004). In multivariate analysis, levels of sCD163<!--> <!-->≥<!--> <!-->1107.3<!--> <!-->ng/mL were associated with CHR<!--> <!-->≥<!--> <!-->0.121 (OR<!--> <!-->=<!--> <!-->3.43, <em>p</em> <!-->=<!--> <!-->0.020), CMI<!--> <!-->≥<!--> <!-->1.70 (OR<!--> <!-->=<!--> <!-->4.25, <em>p</em> <!-->=<!--> <!-->0.005), total cholesterol/HDL-c ratio<!--> <!-->&gt;<!--> <!-->7% (OR<!--> <!-->=<!--> <!-->6.63, <em>p</em> <!-->=<!--> <!-->0.044), as well as with DAS28-ESR<!--> <!-->&gt;<!--> <!-->3.2 (OR<!--> <!-->=<!--> <!-->8.10, <em>p</em> <!-->=<!--> <!-->0.008). Moreover, levels of sCD163 predicted CHR<!--> <!-->≥<!--> <!-->0.121 (AUC<!--> <!-->=<!--> <!-->0.701), cholesterol total/HDL ratio<!--> <!-->&gt;<!--> <!-->7% (AUC<!--> <!-->=<!--> <!-->0.764), and DAS28-ESR<!--> <!-->&gt;<!--> <!-->3.2 (AUC<!--> <!-->=<!--> <!-->0.720).</div></div><div><h3>Conclusion</h3><div>Serum levels of sCD163 could be considered a surrogate of cardiovascular risk and clinical activity in RA.</div></div>","PeriodicalId":45230,"journal":{"name":"Clinica e Investigacion en Arteriosclerosis","volume":"37 1","pages":"Article 100721"},"PeriodicalIF":1.9,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140904932","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comparison of baseline clinical characteristics among people with type 2 diabetes on second-line therapy previously added with dapagliflozin or another oral glucose-lowering drug: AGORA study","authors":"Vicente Pallarés-Carratalá ,&nbsp;Antonio Ruiz-García ,&nbsp;Adalberto Serrano-Cumplido ,&nbsp;Antonio Segura Fragoso ,&nbsp;Verónica Fernández-Pascual ,&nbsp;Beatriz Sánchez-Sánchez ,&nbsp;María Inmaculada Cervera-Pérez ,&nbsp;Francisco Javier Alonso-Moreno ,&nbsp;Ezequiel Arranz-Martínez ,&nbsp;Alfonso Barquilla-García ,&nbsp;Daniel Rey-Aldana ,&nbsp;José Polo García ,&nbsp;Sergio Cinza-Sanjurjo ,&nbsp;on behalf of the Investigators of the AGORA study, of the Spanish Society of Primary Care Physicians SEMERGEN Foundation","doi":"10.1016/j.arteri.2024.05.001","DOIUrl":"10.1016/j.arteri.2024.05.001","url":null,"abstract":"<div><h3>Introduction</h3><div>Type 2 diabetes mellitus (T2D) has acquired epidemic proportions worldwide. In recent years, new oral glucose-lowering drugs (OGLD) have emerged that improve the cardiovascular–kidney–metabolic control in T2D people.</div></div><div><h3>Objectives</h3><div>To compare the baseline clinical–biological characteristics among T2D people to whom had added-on dapagliflozin (DAPA group) or another OGLD (SOC group) second-line hypoglycaemic therapies among the AGORA study population.</div></div><div><h3>Methods</h3><div>This is a multicentre cross-sectional observational study of the baseline characteristics of T2D people recruited through competitive sampling among 46 primary care health centres in Spain for the AGORA study. The inclusion and exclusion criteria of participants, and justification of the sample size are reported. After verifying the data necessary to be evaluated and informed consent, 317 subjects were included to the DAPA group and 288 to the SOC group. Both categorical and continuous variables were analysed and compared with the usual statistics. Cohen's <em>d</em> was used to assess the standardised difference in means.</div></div><div><h3>Results</h3><div>Six hundred and five patients with T2D were assessed (mean age 63.5 [SD<!--> <!-->±<!--> <!-->8.1] years, 61.8% men), whom 17.4% were smokers, 47.6% had obesity, 74.8% hypertension, 87.3% dyslipidaemia, and 41.7% reported physical inactivity, with no significant differences between both comparison groups. The mean (SD) evolution time of T2D was 10.1 (5.6) years. Most baseline clinical–biological characteristics at recruitment were similar in both groups. However, DAPA group was younger (2.9 years), and had lower systolic blood pressure (SBP) (2.8<!--> <!-->mmHg), higher body weight (BW) (3.7<!--> <!-->kg), and higher glycated haemoglobin A_1c (HbA_1c) (0.3%) than SOC group. Only 11.5% of participants had poor glycaemic control (HbA_1c <!-->&gt;<!--> <!-->8%) at recruitment, 54.9% had good glycaemic control (HbA_1c <!-->&lt;<!--> <!-->7%), being significantly lower in the DAPA group (47.3%) than in the SOC group (63.4%). The percentage of T2D patients with high vascular risk (VR) was 46.3%, and 53.7% with very high VR, being significantly higher in the DAPA group (57.4%) than in the SOC group (49.6%).</div></div><div><h3>Conclusions</h3><div>Most baseline cardiovascular–kidney–metabolic characteristics were similar in T2D patients whom had added dapagliflozin on second-line hypoglycaemic therapy as those whom had added-on another OGLD. However, patients whom had added-on dapagliflozin had higher VR, lower SBP, higher BW, and slightly worse HbA_1c control. Future research is necessary to explain the causes of these differences in cardiometabolic control.</div></div>","PeriodicalId":45230,"journal":{"name":"Clinica e Investigacion en Arteriosclerosis","volume":"37 1","pages":"Article 100724"},"PeriodicalIF":1.9,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141443496","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"When “old” lipid lowering therapies not should be discontinued","authors":"Francesco Sbrana,&nbsp;Beatrice Dal Pino","doi":"10.1016/j.arteri.2024.08.002","DOIUrl":"10.1016/j.arteri.2024.08.002","url":null,"abstract":"","PeriodicalId":45230,"journal":{"name":"Clinica e Investigacion en Arteriosclerosis","volume":"37 1","pages":"Article 100732"},"PeriodicalIF":1.9,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142298096","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Las recomendaciones nutricionales: una fácil y difícil tarea para el médico","authors":"Francisco Pérez-Jiménez","doi":"10.1016/j.arteri.2025.500764","DOIUrl":"10.1016/j.arteri.2025.500764","url":null,"abstract":"","PeriodicalId":45230,"journal":{"name":"Clinica e Investigacion en Arteriosclerosis","volume":"37 1","pages":"Article 500764"},"PeriodicalIF":1.9,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143048218","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The athero-contour: A novel tool for global and rapid assessment of atherogenic parameters. A use case in saroglitazar treatment of MAFLD patients","authors":"Kung-Hung Lin ,&nbsp;Nuria Amigo ,&nbsp;Pablo Ortiz ,&nbsp;Cristina Alonso ,&nbsp;Alexander V. Smolensky ,&nbsp;Deven Parmar ,&nbsp;Naga P. Chalasani ,&nbsp;Samer Gawrieh","doi":"10.1016/j.arteri.2024.04.004","DOIUrl":"10.1016/j.arteri.2024.04.004","url":null,"abstract":"<div><h3>Background and aims</h3><div>Comprehensive assessment of pharmacotherapy effects on atherogenic parameters (AP) that influence the risk of cardiovascular disease (CVD) is challenging due to interactions among a large number of parameters that modulate CVD risk.</div></div><div><h3>Methods</h3><div>We developed an illustrative tool, athero-contour (AC), which incorporates weighted key lipid, lipo- and glycoprotein parameters, to readily illustrate their overall changes following pharmacotherapy. We demonstrate the applicability of AC to assess changes in AP in response to saroglitazar treatment in patients with metabolic associated fatty liver disease (MAFLD) in the EVIDENCES IV study.</div></div><div><h3>Results</h3><div>The baseline AC of saroglitazar and placebo groups was worse than the mean of the general population. After 16-week treatment, AC improved significantly in the saroglitazar group due to alterations in very low-density lipoprotein, triglyceride, and glycoproteins.</div></div><div><h3>Conclusion</h3><div>Using AC, we could readily and globally evaluate and visualize changes in AP. AC improved in patients with MAFLD following saroglitazar therapy.</div></div>","PeriodicalId":45230,"journal":{"name":"Clinica e Investigacion en Arteriosclerosis","volume":"37 1","pages":"Article 100723"},"PeriodicalIF":1.9,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141471476","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Documento de recomendaciones de la Sociedad Española de Arteriosclerosis (SEA). La dieta en la prevención cardiovascular. Actualizacion 2024","authors":"Emilio Ros ,&nbsp;Pablo Pérez-Martínez ,&nbsp;Ramón Estruch ,&nbsp;José López-Miranda ,&nbsp;Cristina Soler Ferrer ,&nbsp;Javier Delgado-Lista ,&nbsp;Francisco Gómez-Delgado ,&nbsp;Rosa Solà ,&nbsp;Vicente Pascual","doi":"10.1016/j.arteri.2024.10.001","DOIUrl":"10.1016/j.arteri.2024.10.001","url":null,"abstract":"","PeriodicalId":45230,"journal":{"name":"Clinica e Investigacion en Arteriosclerosis","volume":"37 1","pages":"Article 100741"},"PeriodicalIF":1.9,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142693787","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}